secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2026-07-30T12:06:25+00:00
Accession:  0001178670-26-000060
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q2 product rev $1.17B (+74% YoY); cuts FY TTR guidance to $4.2-4.5B
---------------------------------------------------------------------------

- Q2 2026 net product revenues $1,172M (+74% YoY); TTR franchise $1,030M (+89% YoY).
- GAAP net income $164.5M ($1.23 diluted EPS) vs loss of $72.2M in Q2 2025.
- Full-year 2026 TTR revenue guidance revised down to $4.2-4.5B from $4.4-4.7B (75% growth at midpoint).
- Rare disease revenues $142M (+11% YoY) from GIVLAARI and OXLUMO.
- Initiated Phase 2 trials for ALN-6400 (von Willebrand) and mivelsiran (Down syndrome Alzheimer's).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/0001178670-26-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001178670-26-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer